Defining Clinical Endpoints in Renal Cell Carcinoma

Publication
Article
OncologyONCOLOGY Vol 20 No 6
Volume 20
Issue 6

The manuscripts that comprise this supplement "Defining Clinical Endpoints in Renal Cell Carcinoma" are presented by six leading international clinical and basic investigators, and are derived from their presentations at the roundtable discussion, "Defining Clinical Endpoints in Renal Cell Carcinoma," which took place in Chicago on October 21, 2005, sponsored by Bayer HealthCare.

The manuscripts that comprise this supplement "Defining Clinical Endpoints in Renal Cell Carcinoma" are presented by six leading international clinical and basic investigators, and are derived from their presentations at the roundtable discussion, "Defining Clinical Endpoints in Renal Cell Carcinoma," which took place in Chicago on October 21, 2005, sponsored by Bayer HealthCare. It was given in conjunction with the Fourth International Kidney Cancer Symposium, and featured educational colloquia in lectures, case study presentations, and panel discussions that covered statistical hierarchy in clinical trial endpoints; historic data and endpoints for targeted therapy in various tumor types; clinical trial data with targeted agents and surrogate endpoints in renal cell carcinoma; and treatment in the community.

The faculty presented information on clinical trends and the design of future trials with historic, current, and promising regimens in renal cell carcinoma. Moreover, they proposed a surrogate endpoint (eg, progression-free survival) and tool for early response evaluation based on biologic efficacy (eg, tumor shrinkage). Finally, an additional goal was to produce enduring material for investigators to aid them in current and future study.

The material contained in this volume is thus intended to be a thorough, objective, balanced presentation of clinically oriented research in renal cell carcinoma. I hope that you, the reader, find the information to be timely, pertinent, and useful in patient management in both the community and trial setting, as well as in the design of future clinical trials.

-Ronald M. Bukowski, MD

Disclosures:

Dr. Bukowski acknowledges research funding, consultant/advisory role, and membership on a speaker's bureau for Bayer, Genentech, and Pfizer.

Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Related Content